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A virus-free cell fusion assay relying on the transient transfection of Epstein–Barr virus (EBV) glycoproteins into cells
provides an efficient and quantitative assay for characterizing the viral requirements necessary for fusion of the viral
envelope with the B cell membrane. Extensive cellular fusion occurred when Daudi cells were layered onto Chinese hamster
ovary K1 cells transiently expressing EBV glycoproteins gp42, gH, gL, and gB. This is the first direct evidence that gB is
involved in the process of EBV entry. Moreover, mutational analysis of gB indicates that the cytoplasmic tail contains two
distinct domains that function differentially in the process of fusion. The region from amino acids 802 to 816 is necessary for
productive membrane fusion, while amino acids 817 to 841 comprise a domain that negatively regulates membrane fusion.
© 2001 Academic Press
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HINTRODUCTION
Epstein–Barr virus (EBV) encoded glycoproteins have
prominent functions in several viral processes, including
specific binding to the cellular surface, fusion of the viral
and cellular membranes during viral entry, assembly of
the virion, and egress of the virion from the infected cell
(Kieff, 1996). Inspection of the open reading frames
(ORFs) within the EBV genome suggests that as many as
11 glycoproteins may exist (Baer et al., 1984), several of
which have been characterized as being crucial for the
ability of EBV to gain access into host cells (Hutt-
Fletcher, 1995; Speck et al., 2000). The initial attachment
of EBV to the B cell surface utilizes a specific interaction
between the viral glycoprotein gp350/220 and CD21
through a peptide sequence in gp350/220 that is similar
to the peptide sequence through which the C3d compo-
nent of complement binds CD21 (Fingeroth et al., 1984;
emerow et al., 1989; Tanner et al., 1987). The subse-
uent binding of gp42 with human leukocyte antigen
HLA) class II molecules is critical for infection of B cells
y EBV (Haan et al., 2000; Li et al., 1997). Recombinant
irus lacking gp42 binds to but is not able to infect B cells
Wang and Hutt-Fletcher, 1998), but the mechanism by
hich gp42 initiates membrane fusion is uncertain, as it
nly encodes one stretch of amino acids encompassing
transmembrane domain (Baer et al., 1984).
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106gp42 associates with gH and gL to form a ternary
omplex (Li et al., 1995), and it is likely that upon binding
o HLA class II, gp42 undergoes a conformational
hange that transmits a signal to the gH/gL complex to
nitiate membrane fusion. gL facilitates the proper trans-
ort and processing of gH (Li et al., 1995; Yaswen et al.,
993), and several lines of evidence indicate that the
H/gL complex is vital for the ability of EBV to fuse with
nd penetrate the cell membrane. gH depleted viro-
omes made from EBV glycoproteins can bind to but not
use with B cells and EBV recombinants lacking gH bind
o B cells normally but are unable to fuse with the cellular
embrane (Haddad and Hutt-Fletcher, 1989; Molesworth
t al., 2000; Oda et al., 2000). Additionally, the gH and gL
homologues of other herpesviruses are thought to play a
critical role in membrane fusion (Forrester et al., 1992;
Keay and Baldwin, 1991; Peeters et al., 1992; Rodriguez et
al., 1993). Sequence analysis suggests that gH contains
a hydrophobic domain long enough to span the plasma
membrane in addition to a putative transmembrane do-
main (Baer et al., 1984; Oba and Hutt-Flecher, 1988).
gB has been identified among the a-herpesviruses as
eing necessary for plasma membrane binding and sub-
equent membrane fusion (Cai et al., 1988a; Pereira,
994; Rauh et al., 1991). By analogy, EBV gB would be
redicted to be involved in viral entry, and comparison of
BV gB with its herpes simplex virus 1 (HSV-1) homo-
ogue indicates that they have similar structural motifs
Emini et al., 1987; Gong et al., 1987; Pellett et al., 1985).
owever, sequence analysis suggests they might also
ave distinct biochemical and biological properties
Emini et al., 1987; Gong et al., 1987; Pellett et al., 1985).
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107EBV GLYCOPROTEIN-INDUCED CELL FUSIONEBV gB localizes primarily to the endoplasmic reticulum
(ER) and to the inner and outer nuclear membranes of B
cells undergoing productive infection and is not detected
at high levels at the plasma membrane (Emini et al.,
987; Gong and Kieff, 1990; Gong et al., 1987). The abun-
dant and stable 110-kDa form of gB has only endoglyco-
sidase H-sensitive, high-mannose N-linked oligosaccha-
rides, indicating that this form has not trafficked through
the Golgi apparatus (Gong and Kieff, 1990). Its predom-
inant intracellular localization indicates the function of
gB in the EBV life cycle might be for the assembly and
budding of the virion from the nucleus of a lytically
infected cell. Electron microscopy of cells infected by
gB-null EBV recombinants supports this hypothesis (Lee
and Longnecker, 1997). In addition, antibodies directed
against gB do not neutralize viral binding or infectivity
(Emini et al., 1987; Gong and Kieff, 1990). Thus, the
current model for gB function in the EBV life cycle is in
viral maturation. Though the mature EBV virion appar-
ently lacks detectable amounts of the 110-kDa form of
gB, some reports indicate that a larger form of gB may be
present in the viral membrane at low levels (Emini et al.,
1987; Gong and Kieff, 1990; Gong et al., 1987). Therefore,
a role for gB in EBV entry remains to be established.
HSV-1 or HSV-2 glycoproteins gB, gD, gH, and gL
expressed from plasmid vectors are necessary and suf-
ficient to induce cell fusion of susceptible cells (Mug-
geridge, 2000; Pertel et al., 2001; Turner et al., 1998).
Using a similar transient transfection assay, other stud-
ies have demonstrated that porcine pseudorabies virus
(PRV) gD is dispensable for cell–cell fusion and that
deletions within the cytoplasmic domain of PRV gB alter
the requirements for and modulate the efficiency of this
cellular fusion (Klupp et al., 2000). The deletion of gB
from the EBV genome prevents the production of infec-
tious virus (Herrold et al., 1996), and gB cytoplasmic tail
deletion mutants are unable to complement gB-null EBV
(Lee and Longnecker, 1997). Therefore a virus-free assay
is preferable to determine the requirements for EBV-
induced cell–cell fusion.
Here we describe an efficient and quantitative assay
for studying the EBV glycoproteins required for mem-
brane fusion. Transient expression of gB, gH, gL, and
gp42 in Chinese hamster ovary (CHO-K1) cells was nec-
essary and sufficient to induce the fusion of the CHO-K1
cellular membranes with those of Daudi cells. To further
characterize the involvement of gB in this process, gB
proteins with mutations within the C-terminal cytoplas-
mic domain were assayed for the ability to mediate
fusion. The deletion of the C-terminal 16 amino acids (aa
842–857) of gB had no effect on membrane fusion; how-
ever, a form of gB truncated at amino acid 816 exhibited
a dramatic increase in the level of EBV-induced mem-
brane fusion. Further truncation of the cytoplasmic tail to
amino acid 801 yields a gB that is virtually unable to
function in membrane fusion. The presence of the gB ERretrieval sequence at position 836–839 suggests that the
increase in gB-mediated fusion might be a result of
increased gB surface expression. Point mutations within
the ER signal sequence that alter gB localization were
tested to verify whether altering the location of gB ex-
pression affects EBV-mediated fusion. These mutations
behaved as wild-type gB, indicating that the cytoplasmic
tail of gB contains two domains that have distinct func-
tions in the process of membrane fusion. Amino acids
802 to 816 compose a domain that is absolutely neces-
sary for productive membrane fusion, while amino acids
817 to 841 contain a region that negatively regulates the
ability of gB to induce membrane fusion.
RESULTS
Expression of EBV glycoproteins
The plasmid pCAGGS/MCS permits the expression of
inserted genes under the control of the chicken b-actin
romoter in cooperation with the HCMV-IE enhancer
Niwa et al., 1991) and has been demonstrated to be
apable of driving the efficient expression of multiple
SV-1 glycoproteins when cotransfected in CHO-K1 cells
Pertel et al., 2001). Therefore the coding sequences of
BV gp350, gB, gH, gp42, and gL were inserted into
lasmid pCAGGS/MCS as described under Materials
nd Methods. The expression of each glycoprotein in
HO-K1 cells was then confirmed by cell enzyme-linked
mmunosorbent assay (CELISA). Live CHO-K1 cells ex-
ressing gp350, gB, or gp42 or coexpressing gH along
ith gL were incubated with specific primary antibodies
nd fixed, and then primary antibody binding was de-
ected. As shown in Fig. 1A abundant surface expression
f gp350, gp42, and the gH/gL complex was observed
ompared to cells transfected with vector alone. Con-
ersely, low levels of gB were detected on the surface of
ransfected cells (Fig. 1, gB surface), in accordance with
revious studies that indicate that exogenously ex-
ressed gB as well as gB expressed during lytic infection
ocalizes primarily to ER and nuclear membranes (Emini
t al., 1987; Gong and Kieff, 1990; Gong et al., 1987). To
determine the levels of total gB expression CHO-K1 cells
were fixed, permeablized, and then stained for gB ex-
pression. This method of cellular staining revealed that
gB is indeed efficiently expressed and that the majority of
gB localizes to intracellular membranes, as previously
described (Fig. 1, gB total).
gB, gp42, and the gH/gL complex are necessary and
sufficient for EBV-induced membrane fusion
Studies using HSV-1, HSV-2, and PRV glycoproteins
expressed from plasmid vectors to induce cell fusion of
susceptible cells have relied mainly upon the formation
of multinucleated syncytia to illustrate membrane fusion
(Klupp et al., 2000; Muggeridge, 2000; Pertel et al., 2001;
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108 HAAN, LEE, AND LONGNECKERTurner et al., 1998). Syncytia were observed when
CHO-K1 cells expressing EBV glycoproteins were mixed
with Daudi cells (data not shown). To verify that the
syncytia observed was EBV glycoprotein induced and to
quantify the total level of fusion, a luciferase reporter
gene activation system was utilized. In this assay
CHO-K1 cells were transfected with the EBV glycopro-
FIG. 1. Coexpression of gB, gp42, gH, and gL is necessary and
sufficient for EBV-induced membrane fusion. (A) Cell surface expres-
sion of gp350, gB, gp42, and the gH/gL complex as measured by
CELISA. CHO-K1 cells were transfected with a total of 4.0 mg of the
ppropriate glycoprotein plasmid. Twelve hours after transfection, cells
ere plated onto 96-well plates and incubated for 24 h. For identifica-
ion of surface expression, cells were treated with the appropriate
rimary antibody and then fixed. Cells were sequentially subjected to
n anti-mouse IgG biotin-conjugated antibody and a streptavidin–
orseradish peroxidase conjugate. After the addition of peroxidase
ubstrate optical density readings at 370 nm were obtained. For the
etection of total intracellular and surface expression (gB–total), cells
ere fixed, permeablized, and then incubated with the appropriate
rimary antibody. The level of nonspecific staining for each primary
ntibody on CHO-K1 cells transfected with empty vector is indicated in
he left column, opposed to glycoprotein-specific stain on the right. The
alues for three replicate samples are shown. (B) CHO-K1 cells were
ransfected with the indicated EBV glycoproteins and/or control vector
s well as the luciferase reporter plasmid. Daudi cells were transfected
ith T7 RNA polymerase. Twelve hours after tranfection Daudi cells
ere plated over the CHO-K1 cells. Luciferase activity was measured
4 h after cocultivation. The mean relative luminosity units from three
eparate experiments run in duplicate are illustrated. The relative
uciferase activity of the vector transfected CHO-K1 cells is normalized
o one luciferase unit. Other values indicate fold induction above that of
he vector control.teins of interest in addition to a plasmid containing the
luciferase reporter gene under the control of the T7 RNApolymerase. These cells were then mixed with Daudi
cells transfected with a plasmid containing T7 RNA poly-
merase driven by the chicken b-actin promoter and the
MV-IE enhancer. Because the contents of the CHO-K1
ells must combine with those of the Daudi cells in order
or T7 RNA polymerase to turn on expression of the
uciferase gene, the level of luciferase activity accurately
easures the amount of cellular fusion between the
ifferent cell populations.
To determine the requirements for EBV-induced mem-
rane fusion, CHO-K1 cells were transfected with the
BV glycoproteins gp350, gB, gp42, gH, and gL and
ixed with Daudi cells. As shown in Fig. 1B, these
lycoproteins were capable of inducing efficient cellular
embrane fusion as measured by luciferase activity, as
pposed to CHO-K1 cells transfected with the empty
ector (Fig. 1B, V and gp350, gB, gp42, gH/gL). To deter-
ine the minimal set of glycoproteins necessary for
usion, EBV glycoproteins were serially subtracted from
he CHO-K1 cells and fusion activity was quantified. The
mission of gp350 expression did not significantly affect
BV-induced membrane fusion; however, the omission of
B, gp42, or the gH/gL complex resulted in CHO-K1 cells
hat were unable to fuse with Daudi cells (Fig. 1B). These
esults indicate that the proteins required for membrane
usion are gB, gp42, gH, and gL.
ifferential ability of gB deletion mutants to induce
embrane fusion
The results in Fig. 1B suggest a previously undefined
ole for gB in EBV entry. The mature form of gB consists
f three separate domains: a large amino-terminal
ctodomain, three hydrophobic regions through which it
nserts into the membrane, and a cytoplasmic tail (Fig. 2).
revious studies with HSV-1 and PRV gB have suggested
hat the cytoplasmic tails of these gB molecules contain
mportant domains that are involved in regulating viral-
nduced fusion (Baghian et al., 1993; Cai et al., 1987;
Gage et al., 1993; Klupp et al., 2000). Since the cytoplas-
ic tail of gB is important for the egress of EBV particles
rom the nucleus (Lee and Longnecker, 1997), the extent
o which gB deletion mutants gBD841, gBD816, and
BD801 (Fig. 2) affect virus induced fusion could not be
nvestigated.
Analysis of the surface expression by CELISA of these
eletion mutants indicates that as previously demon-
trated (Lee and Longnecker, 1997), gBD816 and gBD801
are abundantly expressed on the cell surface and that
the profile of gBD841 surface expression is similar to that
of wild-type gB (Fig. 3A). Total cell CELISA staining also
indicates that gBD841 is expressed intracellularly at lev-
els similar to that of wild-type gB (data not shown) (Lee
and Longnecker, 1997). Expression of wild-type gB from
the vector pSGS (Stratagene) along with that of gp42, gH,
and gL from pCAGGS/MCS in CHO-K1 cells results in
positio
109EBV GLYCOPROTEIN-INDUCED CELL FUSIONsimilar fusion with Daudi cells as that observed when
expressing gB from pCAGGS/MCS (Figs. 1B and 3B).
Similar results were obtained when using the deletion
mutant gBD841 (Fig. 3B). However, when gBD816 was
substituted for wild-type gB, a threefold increase in lu-
ciferase activity was observed compared to that of wild-
type gB (Fig. 3B). Conversely, little luciferase activity
above background was observed when expressing
gBD801 in place of wild-type gB (Fig. 3B). This result
suggests two different possible models for the involve-
ment of the cytoplasmic tail of gB in EBV-induced mem-
brane fusion. The localization of wild-type gB primarily to
the ER and nuclear membranes is dependent upon the
ER retrieval sequence of the four repeated arginines at
amino acids 836–839 in the cytoplasmic tail of gB (Fig. 2)
(Lee, 1999). It is possible that the increased surface
expression of gBD816 due to the removal of the ER
retention signal is sufficient for the increased level of
fusion and that deletion of amino acids 802 to 857 re-
moves a domain necessary for fusion, disabling it de-
spite abundant surface expression. Alternatively the do-
main from 802 to 816 might be necessary for fusion and
a domain within the region of 817 to 841 might be in-
volved in negatively regulating fusion. In this model, the
level of gB surface expression would not reflect fusion
potential since adequate amounts of wild-type gB are
present to allow fusion to occur.
Increased gB surface expression does not
correspond with increased fusion activity
If the fusion activity of gB is dependent upon the level
of surface expression, then point mutations within the
FIG. 2. Schematic representation of gB. The 685-amino-acid N-termin
are specified. The sequence of the 104-amino-acid cytoplasmic tail is
retrieval sequence at position 836–839 is in italics. The sequences at
under the wild-type sequence.arginine repeat that abrogate ER retrieval and cause
predominant plasma membrane localization should facil-itate increased levels of fusion similar to that observed
with gBD816. Figure 2 illustrates the four point mutants
within the 836–839 ER retention sequence that were
used to assay the dependence of fusion on the level of
gB expression in the plasma membrane. In accordance
with previous results, gB with the sequence RKRR from
836 to 839 is expressed at low levels on the plasma
membrane similar to the findings observed in wild-type
gB (Fig. 4A), but localizes primarily to the intracellular
region (data not shown) (Lee, 1999). gB mutants contain-
ing the sequence KKKK, RTTR, or REER from amino acids
836 to 839 show abundant surface expression (Fig. 4A).
However, all ER retrieval sequence mutants exhibited the
ability to mediate membrane fusion similar to that of
wild-type gB (Fig. 4B). These results would indicate that
low levels of gB surface expression at the plasma mem-
brane, as detected with wild-type gB, are sufficient for
fusion and that the region from 817 to 841 is involved in
negatively regulating fusion since deletion of this region
greatly enhances glycoprotein induced fusion.
gB deletion mutants do not significantly alter gp42 or
gH/gL complex expression
These experiments indicate that a low level of gB on
the surface of the plasma membrane is adequate to
induce membrane fusion and that the phenotype of
gBD801 and gBD816 cannot be explained by altered
expression of these mutants. Yet it is possible that the
region from 801 to 841 is responsible for regulating the
expression of the ternary gp42/gH/gL complex, which
has been shown to be vital for the fusion of the EBV
envelope with the B cell membrane (Haddad and Hutt-
cellular domain and the 68-amino-acid putative transmembrane region
with the location of the three truncation mutations indicated. The ER
n 836–839 for the four ER retrieval sequence point mutants are listedal extra
givenFletcher, 1989; Li et al., 1995; Wang and Hutt-Fletcher,
1998). The surface expression of all four viral glycopro-
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110 HAAN, LEE, AND LONGNECKERteins was therefore determined when coexpressed in
CHO-K1 cells. As shown in Fig. 5, cotransfection of either
gBD801 or gBD816 does not result in a significant or
eproducible change in the levels of gp42 or gH/gL
urface expression as compared to cells cotransfected
ith wild-type gB, despite differing levels of gB surface
xpression. These data suggest that the gB cytoplasmic
ail does not function to control or alter the expression of
he other members of the fusion machinery.
DISCUSSION
Previous data have indicated that EBV gB plays a role
FIG. 3. Differential ability of gB deletion mutants to induce membrane
usion. (A) Cell surface expression of wild-type gB, gBD841, gBD816,
and gBD801 as measured by CELISA. CHO-K1 cells were transfected
with 4.0 mg of the appropriate plasmid. Twelve hours after transfection
cells were plated onto 96-well plates and incubated for 24 h. Cells were
then treated with the appropriate primary antibody and then fixed. Cells
were sequentially subjected to an anti-mouse IgG biotin-conjugated
antibody and a streptavidin–horseradish peroxidase conjugate. After
the addition of peroxidase substrate optical density readings at 370 nm
were obtained. The values for three replicate samples are shown. (B)
CHO-K1 cells were transfected with the indicated form of gB in addition
to gp42, gH, and gL, as well as the luciferase reporter plasmid. Daudi
cells were transfected with T7 RNA polymerase. Twelve hours after
tranfection Daudi cells were plated over the CHO-K1 cells. Luciferase
activity was measured 24 h after cocultivation. The mean relative
luminosity units from three separate experiments run in duplicate are
illustrated. The relative luciferase activity of the vector transfected
CHO-K1 cells is normalized to one luciferase unit. Other values indicate
fold induction above that of the vector control.n the egress of virions from cells undergoing lytic rep-
ication (Lee and Longnecker, 1997). In the current study
l
vwe demonstrate that gB also functions in the process of
EBV-induced cell to cell fusion. Membrane fusion oc-
curred independent of gp350, suggesting that the inter-
action between gp350 and CD21 is not required for viral
fusion but is strictly involved in the attachment of the
virion to the cellular membrane. Previous studies have
demonstrated that the EBV glycoproteins gp42, gH, and
gL are necessary for the fusion of the viral envelope with
the B cell membrane (Molesworth et al., 2000; Oda et al.,
2000; Wang and Hutt-Fletcher, 1998). In agreement with
these results, gp42, gH, and gL were also required for
EBV-induced membrane fusion. Taken together these
results indicate that the concerted action of gB, gp42, gH,
FIG. 4. Point mutations that alter the localization of gB do not affect
fusion activity. (A) Cell surface expression of wild-type gB, gB-RKRR,
gB-KKKK, gB-RTTR, and gB-REER as measured by CELISA. CHO-K1
cells were transfected with 4.0 mg of the appropriate plasmid. Twelve
ours after transfection cells were plated onto 96-well plates and
ncubated for 24 h. Cells were treated with the appropriate primary
ntibody and then fixed. Cells were sequentially subjected to an anti-
ouse IgG biotin-conjugated antibody and a streptavidin–horseradish
eroxidase conjugate. After the addition of peroxidase substrate opti-
al density readings at 370 nm were obtained. The values for three
eplicate samples are shown. (B) CHO-K1 cells were transfected with
he indicated form of gB in addition to gp42, gH, and gL, as well as the
uciferase reporter plasmid. Daudi cells were transfected with T7 RNA
olymerase. Twelve hours after tranfection Daudi cells were plated
ver the CHO-K1 cells. Luciferase activity was measured 24 h after
ocultivation. The mean relative luminosity units from three separate
xperiments run in duplicate are illustrated. The relative luciferase
ctivity of the vector transfected CHO-K1 cells is normalized to oneuciferase unit. Other values indicate fold induction above that of the
ector control.
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111EBV GLYCOPROTEIN-INDUCED CELL FUSIONand gL might be important in promoting the fusion of the
viral membrane with the B cell membrane.
Cell fusion induced by HSV-1 and HSV-2 requires the
expression of glycoproteins gD, gB, gH, and gL (Mug-
geridge, 2000; Pertel et al., 2001; Turner et al., 1998). It is
likely that EBV gB, gH, and gL fulfill a similar function as
that of the HSV homologues. Likewise it seems that gD
and gp42, both of which are involved in binding the
cognate coreceptors of each respective virus, might be
functional homologues, despite a lack of sequence ho-
mology. The observation that gp350 is dispensable for
cellular fusion indicates that the CD21–gp350 interaction
plays an accessory role in EBV entry. This parallels the
role of gC in HSV entry, in that cellular fusion occurs
independent of gC and that gC deleted HSV-1 recombi-
nants are still viable but have a reduced level of infec-
tivity (Herold et al., 1991). This is similar to the observa-
tion that gp350 deleted EBV recombinants are able to
infect B cells, also at a reduced efficiency (Janz et al.,
2000).
Previous studies concerning EBV gB demonstrate its
primary localization to the ER and the nuclear membrane
of B cells undergoing productive infection (Emini et al.,
1987; Gong and Kieff, 1990; Gong et al., 1987), which is
ompatible with the function of gB in the assembly and
udding of the virion. The dependence of EBV-induced
FIG. 5. gB deletion mutants do not significantly alter the surface
xpression of the ternary gp42/gH/gL complex. CHO-K1 cells were
otransfected with 0.5 mg of the indicated gB plasmid, pF25, and pF85,
2.0 mg of pF42, and 0.8 mg of a pT7ENCLuc. Twelve hours after
ransfection CHO-K1 cells were plated onto 96-well plates and incu-
ated for 24 h. Cells were treated with the appropriate primary antibody
nd then fixed. Cells were sequentially subjected to an anti-mouse IgG
iotin-conjugated antibody and a streptavidin–horseradish peroxidase
onjugate. After the addition of peroxidase substrate optical density
eadings at 370 nm were obtained. The values for three replicate
amples are shown. Columns designated C represent cellular staining
sing a nonspecific mouse IgG2A antibody. Similar expression values
ere obtained when CHO-K1 cells were transfected with 0.5 mg of the
indicated gB plasmid, pF25, and pF85 or 2.0 mg of pF42 and supple-
ented with vector DNA for a total of 5 mg.ell fusion on gB is the first evidence that gB might be
nvolved in EBV entry despite low levels of expression on
v
othe cell surface and presumably on the viral membrane
(Fig. 1A) (Emini et al., 1987). Mutational analysis of gB
indicates that different regions in the cytoplasmic tail
modulate the process of membrane fusion. The region
from amino acids 802 to 816 promotes productive mem-
brane fusion, while the adjacent domain from position
817 to 841 negatively regulates membrane fusion. Stud-
ies involving HSV-1 and PRV gB also suggest that the
cytoplasmic tail of gB plays a critical role in viral-induced
membrane fusion (Baghian et al., 1993; Cai et al., 1987;
age et al., 1993; Klupp et al., 2000; Pereira, 1994).
The cytoplasmic tail of HSV-1 gB has two regions with
predicted a-helices, H17a and H17b. Mutations in the
cytoplasmic domain of HSV-1 gB that disrupt or eliminate
the predicted H17b a-helix have a phenotype similar to
hat of the EBV gBD816 mutant in that these mutants
xhibit a hyperfusion phenotype (Baghian et al., 1993; Cai
t al., 1988b; Gage et al., 1993). The observation that the
a-helix H17b in HSV-1 gB correlates with amino acids
822–837 in EBV gB, the domain that negatively regulates
EBV-induced membrane fusion, suggests that this region
in EBV gB might also form an a-helix that functions in a
anner similar to that of H17b in HSV-1 fusion. Deletion
nalysis of the PRV gB cytoplasmic tail also indicates
hat a homologous a-helix is important for regulating PRV
fusion (Klupp et al., 2000). The striking similarity in the
unction of these gB molecules in viral entry intimates
hat the extracellular domain of EBV gB might also play a
ole in entry. Conversely, it also suggests that a-herpes-
virus gB molecules might be involved in viral maturation,
though perhaps to a lesser extent than that of EBV gB.
EBV is associated with multiple diseases of epithelial
cell origin (Cohen, 2000) and several studies indicate
that EBV can infect epithelial cells in tissue culture (Fin-
geroth et al., 1999; Li et al., 1992; Yoshiyama et al., 1997).
The data presented here illustrate that gB, gp42, and the
gH/gL complex are required for EBV-induced fusion with
the B cell membrane. However, multiple lines of evi-
dence indicate that the entry requirements of EBV differ
from epithelial cells to B cells and might even vary
depending on the specific epithelial cell line infected
(Janz et al., 2000; Li et al., 1995; Molesworth et al., 2000;
Yoshiyama et al., 1997). Specifically, epithelial cell infec-
tion appears to occur independent of gp42 (Wang and
Hutt-Fletcher, 1998; Wang et al., 1998). The cell fusion
assay described here provides a convenient means to
determine whether EBV-induced fusion differs among
cell lineages and whether glycoproteins other than those
mentioned modulate the extent of EBV-induced mem-
brane fusion. Experiments with HSV indicate that several
accessory glycoproteins are capable of modulating
membrane fusion (Balan et al., 1994; Davis et al., 1994;
Debroy et al., 1985; Haanes et al., 1994; MacLean et al.,
993; Pogue and Spear, 1987). By analogy with a-herpes-
iruses it is likely that the EBV glycoproteins gM and gN
r the EBV homologue of HSV UL24 encoded by the
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112 HAAN, LEE, AND LONGNECKERBXRF1 ORF might also have the ability to modulate EBV-
induced fusion. The capability of modifying EBV infection
of epithelial cells has been attributed to glycoprotein
gp150 (Borza and Hutt-Fletcher, 1998); however, it is
unclear whether this occurs at the level of binding or
membrane fusion. Besides gp150, the EBV genome en-
codes another unique glycoprotein, gp78, the product of
the BILF2 ORF, to which no function has yet been attrib-
uted (Mackett et al., 1990). The advent of a virus-free
fusion assay now enables a method by which to expedite
the study of how other viral glycoproteins are involved in
the fusion of the EBV viral envelope with the cellular
membrane of the target cell.
MATERIALS AND METHODS
Cells and antibodies
CHO-K1 cells were provided by P. G. Spear and pas-
saged in Ham’s F12 medium (Gibco BRL) supplemented
with 10% serum and antibiotics. Daudi (Klein et al., 1976)
cells were grown in RPMI medium (Gibco BRL) supple-
mented with 10% serum and antibiotics. Monoclonal an-
tibodies E1D1 and F-2-1 were the gift of L. Hutt-Fletcher
and recognize the gH/gL complex and gp42, respectively
(Li et al., 1995; Oba and Hutt, 1988; Strnad et al., 1982).
A21 and L2 were purchased from Chemicon and are
irected against gp350 and gB, respectively. Murine spe-
ific biotinylated anti-IgG conjugate was purchased from
igma. The streptavidin–horseradish peroxidase conju-
ate was purchased from Pharmacia and the immuno-
lobulin isotype-matched control IgG2a antibody was
urchased from Pharmingen.
lasmids
The coding sequence of gL was excised from pSG194
sing EcoRI and BglII and inserted into pCAGGS-MCS
Kobasa et al., 1997), a gift from Y. Kowaoka, cut with the
ame enzymes to create pF25. pF42 was generated by
as excising the EcoRI and BglII fragment from pPS202
nd inserting it into pCAGGS-MCS cut with the same
nzymes. pPS202 was constructed by PCR amplification
f the gp42 coding sequence from the B95.8 EBV ge-
ome using primers incorporating a ClaI restriction site
nto the 59UTR and a BglII restriction site into the 39UTR
f gp42 and then inserted into pSG5 (Stratagene). The
oding sequence of gH was PCR amplified from pSG181
ncorporating a ClaI restriction site into the 59UTR and a
glII restriction site into the 39UTR and inserted into
CAGGS-MCS cut with the same enzymes to generate
F85. pF110 was created by PCR amplification of RH1
ncorporating the EcoRI restriction site from pSG5 into
he 59UTR and a ClaI restriction site into the 39UTR and
nserted into pCAGGS-MCS cut with the same enzymes.
he coding sequence of gp350 was PCR amplified from
he B95.8 EBV genome incorporating a KpnI restrictionite into the 59UTR and a BglII restriction site into the
9UTR and inserted into pCAGGS-MCS cut with the same
nzymes to create pF350.
Plasmid pCAGT7 expressing T7 RNA polymerase un-
er the control of the chicken b-actin promoter and the
MV-IE enhancer and plasmid pT7EMCLuc expressing
he firefly luciferase gene under control of the T7 pro-
oter were both gifts from Y. Matsuura (Okuma et al.,
999). EBV gB deletion mutants gBD841, gBD816, and
BD801 and the gB cytoplasmic tail point mutants gB
RKRR), gB (KKKK), gB (RTTR), and gB (REER) as well as
he wild-type gB in pSG5 (Stratagene) are as previously
escribed (Lee, 1999; Lee and Longnecker, 1997).
ell enzyme-linked immunosorbent assay
Subconfluent CHO-K1 cells were transfected with 4.0
mg of the appropriate plasmid(s) DNA using Lipo-
fectamine 2000 (Gibco BRL) in Opti-MEM (Gibco BRL)
according to the manufacturer’s protocol. Twelve hours
after transfection the Lipofectamine 2000 solution was
removed from the CHO-K1 cells, and the cells were
washed with PBS, detached using PBS with 0.5 mM
EDTA, and plated onto 96-well plates.
After 24 h the cells were washed twice with PBS. For
the detection of total intracellular and surface expres-
sion, cells were fixed in PBS plus 2% formaldehyde and
0.2% gluteraldehyde, permeablized with 2 mM magne-
sium chloride, 0.02% (octylphenoxy)polyphenoxyethanol,
and 0.01% deoxycholic acid, and then incubated with the
appropriate primary antibody in PBS with 3% bovine
serum albumin (BSA) for 30 min. For identification of
surface expression, cells were washed twice with PBS,
treated with the appropriate primary antibody in PBS with
3% BSA for 30 min, and then fixed with PBS plus 2%
formaldehyde and 0.2% gluteraldehyde. Subsequent to
primary antibody incubation, cells were washed five
times with PBS with 3% BSA and incubated with an
anti-mouse IgG biotin-conjugated antibody diluted 1:500
in PBS with 3% BSA for 30 min. After the secondary
antibody was removed, cells were again washed five
times with PBS with 3% BSA and incubated with strepta-
vidin–horseradish peroxidase conjugate in PBS with 3%
BSA plus 0.1% Tween at a dilution of 1 to 20,000 for 30
min. Cells were then washed five times in PBS with 3%
BSA plus 0.1% Tween and subjected to 100 ml of perox-
idase substrate (BioFX). Optical density (OD) readings at
370 nm were obtained using a SprectraMax 250 (Molec-
ular Devices) plate spectrophotometer.
Cell fusion assays
Subconfluent 6-well plates containing CHO-K1 cells
were transfected with 0.5 mg of pF25, pF85, pF110, and
pF350, 2.0 mg of pF42, and 0.8 mg of pT7ENCLuc. For
experiments in which specific glycoproteins were seri-
ally subtracted, the amount of DNA per transfection was
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113EBV GLYCOPROTEIN-INDUCED CELL FUSIONkept constant by the addition of empty vector DNA. Daudi
cells were electroporated with 50 mg of pCAGT7 using a
Gene Pulser (Bio-Rad). A total of 2 3 107 cells were
lectroporated in 0.4-cm gap cuvettes (Bio-Rad) at 0.280
V and 960-mF capacitance. Twelve hours after transfec-
ion, the Lipofectamine 2000 solution was removed from
he CHO-K1 cells, the cells were washed with PBS, and
3 106 viable Daudi cells were plated on top. Ham’s F12
edium was then added to a total volume of 5 ml.
Twenty-four hours after the Daudi cell overlay, lucif-
rase activity was quantified using the Luciferase Re-
orter Assay System (Promega). CHO-K1/Daudi mono-
ayers were washed twice with PBS and then lysed in
00 ml of passive lysis buffer under gentle agitation for 20
in. Twenty microliters of cell supernatant was added to
00 ml of beetle luciferin substrate, the mixture was
riefly vortexed, and luminosity readings were obtained
sing a TD-20/20 luminometer (Turner Designs).
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